ZNF687 Mutations in an Extended Cohort of Neoplastic Transformations in Paget's Disease of Bone: Implications for Clinical Pathology.


Journal

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640

Informations de publication

Date de publication:
10 2020
Historique:
received: 29 10 2019
revised: 17 01 2020
accepted: 27 01 2020
pubmed: 28 2 2020
medline: 16 6 2021
entrez: 28 2 2020
Statut: ppublish

Résumé

Neoplastic transformation is a rare but serious complication of Paget's disease of bone (PDB), occurring in fewer than 1% of individuals with polyostotic disease. Their prognosis is poor, with less than 50% surviving 5 years. In 2016, the genetic alteration of giant cell tumor (GCT) complicating PDB was identified as a founder germline mutation (P937R) in the ZNF687 gene. However, the study population was exclusively of Italian descent, and patients of different ethnic origins were not studied. To fill this gap, herein we performed mutation analysis of ZNF687 in a GCT in the pelvis of a 45-year-old black American woman with polyostotic PDB. The P937R mutation in ZNF687 was found in her tumor but, as expected, the ancestral haplotype that characterizes the Italian GCT/PDB patients was not found. Furthermore, we identified two additional Italian GCT/PDB patients with this ZNF687 mutation, now constituting a cohort of 18 GCT/PDB cases, all harboring the identical mutation. We also searched for ZNF687 mutations in a unique collection of tumor tissues derived from Italian PDB patients, including 28 osteosarcomas (OS/PDB), 8 undifferentiated sarcomas (SRC/PDB), 1 fibrosarcoma (FS/PDB), and 1 chondrosarcoma (CS/PDB). We identified the P937R mutation in one SRC/PDB and a different ZNF687 mutation (R331W) in 1 of 28 pagetic osteosarcomas. Thus, whereas GCT/PDB pathogenesis globally seems to involve the P937R mutation in ZNF687, other neoplasms associated with PDB seem to be less related to mutations in this gene. Finally, we identified the G34W mutation in the H3F3A gene in the maxillary tumor masses of two PDB patients, defining them as conventional GCT rather than GCT/PDB. Thus, combined molecular analysis of H3F3A and ZNF687 is essential to clarify the origin and diagnosis of tumors in PDB. © 2020 American Society for Bone and Mineral Research.

Identifiants

pubmed: 32106343
doi: 10.1002/jbmr.3993
doi:

Substances chimiques

DNA-Binding Proteins 0
ZNF687 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1974-1980

Informations de copyright

© 2020 American Society for Bone and Mineral Research.

Références

Whyte MP. Clinical practice. Paget's disease of bone. N Engl J Med. 2006;355:593-600.
Ralston SH. Clinical practice. Paget's disease of bone. N Engl J Med. 2013;368:644-50.
Reddy SV, Menaa C, Singer FR, Demulder A, Roodman GD. Cell biology of Paget's disease. J Bone Miner Res. 1999;14:3-8.
Galson DL, Roodman GD. Pathobiology of Paget's disease of bone. J Bone Metab. 2014;21:85-98.
Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70:1582-8.
Hocking LJ, Lucas GJ, Daroszewska A, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet. 2002;11:2735-9.
Cundy T. Paget's disease of bone. Metabolism. 2018;80:5-14.
Haibach H, Farrell C, Dittrich FJ. Neoplasms arising in Paget's disease of bone: a study of 82 cases. Am J Clin Pathol. 1985;83:594-600.
Jattiot F, Goupille P, Azais I, et al. Fourteen cases of sarcomatous degeneration in Paget's disease. J Rheumatol. 1999;26:150-5.
Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res. 2006;21(Suppl 2):P58-63.
Rendina D, De Filippo G, Ralston SH, et al. Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone. J Bone Miner Res. 2015;30:257-63.
Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479-82.
Lu C, Jain SU, Hoelper D, et al. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science. 2016;352:844-9.
Fang D, Gan H, Lee JH, et al. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science. 2016;352:1344-8.
Divisato G, Scotto di Carlo F, Pazzaglia L, et al. The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences. Oncotarget. 2017;8:63121-31.
Divisato G, Formicola D, Esposito T, et al. ZNF687 mutations in severe Paget disease of bone associated with giant cell tumor. Am J Hum Genet. 2016;98:275-86.
Divisato G, Scotto di Carlo F, Petrillo N, Esposito T, Gianfrancesco F. ZNF687 mutations are frequently found in pagetic patients from South Italy: implication in the pathogenesis of Paget's disease of bone. Clin Genet. 2018;93:1240-4.
Ziambaras K, Totty WA, Teitelbaum SL, Dierkes M, Whyte MP. Extraskeletal osteoclastomas responsive to dexamethasone treatment in Paget bone disease. J Clin Endocrinol Metab. 1997;82:3826-34.
Gong F, Chiu LY, Cox B, et al. Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination. Genes Dev. 2015;29:197-211.
Savitsky P, Krojer T, Fujisawa T, et al. Multivalent histone and DNA engagement by a PHD/BRD/PWWP triple reader cassette recruits ZMYND8 to K14ac-rich chromatin. Cell Rep. 2016;17:2724-37.
Spruijt CG, Luijsterburg MS, Menafra R, et al. ZMYND8 co-localizes with NuRD on target genes and regulates poly(ADP-ribose)-dependent recruitment of GATAD2A/NuRD to sites of DNA damage. Cell Rep. 2016;17:783-98.
Malovannaya A, Lanz RB, Jung SY, et al. Analysis of the human endogenous coregulator complexome. Cell. 2011;145:787-99.
Eberl HC, Spruijt CG, Kelstrup CD, Vermeulen M, Mann M. A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics. Mol Cell. 2013;49:368-78.
Nishibuchi G, Shibata Y, Hayakawa T, et al. Physical and functional interactions between the histone H3K4 demethylase KDM5A and the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem. 2014;289:28956-70.
Bhaskar SN, Bernier JL, Godby F. Aneurysmal bone cyst and other giant cell lesions of the jaws: report of 104 cases. J Oral Surg Anesth Hosp Dent Serv. 1959;17:30-41.
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumour of bone. J Bone Joint Surg Am. 1987;69:106-14.
Bertoni F, Unni KK, Beabout JW, Ebersold MJ. Giant cell tumor of the skull. Cancer. 1992;70:1124-32.
Presneau N, Baumhoer D, Behjati S, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1:113-23.

Auteurs

Federica Scotto di Carlo (F)

Institute of Genetics and Biophysics, National Research Council of Italy, Naples, Italy.

Laura Pazzaglia (L)

Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Steven Mumm (S)

Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, MO, USA.
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children-St. Louis, St. Louis, MO, USA.

Maria S Benassi (MS)

Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Annarosaria De Chiara (A)

Pathology Division, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy.

Alessandro Franchi (A)

Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Antonina Parafioriti (A)

Department of Pathology, Orthopaedic Institute Gaetano Pini, Milan, Italy.

Alberto Righi (A)

Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Teresa Esposito (T)

Institute of Genetics and Biophysics, National Research Council of Italy, Naples, Italy.
IRCCS INM Neuromed, Pozzilli, Italy.

Michael P Whyte (MP)

Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, MO, USA.
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children-St. Louis, St. Louis, MO, USA.

Fernando Gianfrancesco (F)

Institute of Genetics and Biophysics, National Research Council of Italy, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH